Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NVCT
#3035
Nuvectis Pharma, Inc. Common Stock
8.8
6
-0.78%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-0.78%
Monthly Change
+0.68%
6 month change
+32.24%
Year Change
+27.85%
Previous Close
8.9
3
Open
8.8
6
Bid
Ask
Low
8.8
6
High
8.8
6
Volume
17
Markets
US Stock Market
Healthcare
NVCT
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
14.75 M
17.77 M
23.39 M
26.49 M
—
Valuation ratios
Enterprise value
90.64 M
128.2 M
108.05 M
168.41 M
651.59 M
Price to earnings ratio
-4.97
-5.8
-4.87
-5.72
-25.14
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
7
8.08
7.56
10.29
44.81
Price to book ratio
6.68
10.57
9.53
8.94
16.39
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.94
1.16
1.02
0.83
0.85
Return on equity %
1.34
1.82
1.96
1.44
1.34
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
—
—
Operating margin %
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
3.3
2.75
2.09
2.38
11.4
Inventory turnover
—
—
—
—
—
Asset turnover
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.07
1.03
0.72
0.73
0.75
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
1.58
1.23
1.08
1.45
5.76
Net current asset value per share
1.61
1.23
1.09
1.45
5.8
Tangible book value per share
1.12
0.78
0.57
0.84
3.74
Working capital per share
1.12
0.78
0.57
0.84
3.74
Book value per share
1.12
0.78
0.57
0.84
3.74
News
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Nuvectis Pharma adds former Intra-Cellular exec to board of directors
Nuvectis initiates phase 1b program for cancer drug NXP900
Nuvectis (NVCT) Q2 Loss Widens 43%
Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright
Nuvectis halts NXP800 development for ovarian cancer, shifts focus
Nuvectis reports positive drug interaction study for cancer drug NXP900
Friday’s Insider Activity: Top Buys and Sells in US Stocks
Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference